AnaptysBio (NASDAQ: ANAB) grants CFO 25,765 restricted stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Murphy Christopher M. reported acquisition or exercise transactions in this Form 4 filing.

AnaptysBio, Inc. reported a compensation-related equity grant to its Chief Financial Officer, Christopher M. Murphy. On May 11, 2026, he received 25,765 restricted stock units, each representing a right to receive one share of common stock for no cash consideration.

The RSUs vest in four equal annual installments of 25% each, starting on May 11, 2027, as long as he continues providing service to the company on each vesting date. Following this grant, Murphy holds 25,765 RSUs directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Murphy Christopher M.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	25,765	$0.00	--

Holdings After Transaction: Restricted Stock Units — 25,765 shares (Direct, null)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The RSUs vests as to 25% of the total RSUs annually commencing on May 11, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

RSUs granted: 25,765 units RSUs held after grant: 25,765 units Vesting schedule: 25% annually +1 more

4 metrics

RSUs granted 25,765 units Grant to CFO on May 11, 2026

RSUs held after grant 25,765 units Total restricted stock units directly owned post-transaction

Vesting schedule 25% annually RSUs vest in four annual installments starting May 11, 2027

Exercise/settlement price $0.00 per share No cash consideration required upon settlement of RSUs

Key Terms

Restricted Stock Units, contingent right, vests, settlement

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement..."

vests financial

"The RSUs vests as to 25% of the total RSUs annually commencing on May 11, 2027..."

settlement financial

"receive 1 share of the Issuer's Common Stock upon settlement for no consideration."

Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.

Form 4 Insider Transactions: What Each Field Means →

05/13/2026 - 05:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murphy Christopher M.

(Last)

(First)

(Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/11/2026		A		25,765		⁽²⁾	⁽²⁾	Common Stock	25,765	$0	25,765	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 25% of the total RSUs annually commencing on May 11, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Dan Faga, Attorney-in-fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did AnaptysBio (ANAB) disclose for its CFO?

AnaptysBio disclosed that its Chief Financial Officer, Christopher M. Murphy, received 25,765 restricted stock units as an equity award. These units are compensation-related and provide a right to receive common shares without cash payment when they vest and settle.

How many RSUs did the AnaptysBio (ANAB) CFO receive and on what date?

The CFO received 25,765 restricted stock units on May 11, 2026. Each RSU represents a contingent right to receive one share of AnaptysBio common stock upon settlement, with no exercise price or cash consideration required from the executive.

What is the vesting schedule for the AnaptysBio (ANAB) CFO’s RSUs?

The RSUs vest in four equal annual installments of 25% each, beginning on May 11, 2027. Vesting continues annually until fully vested, provided the CFO remains in service to AnaptysBio on each applicable vesting date.

Does the AnaptysBio (ANAB) Form 4 reflect an open-market stock purchase or sale?

No, the Form 4 reflects a grant of restricted stock units as compensation, not an open-market purchase or sale. The units are awarded at no cost and will convert into common shares only as they vest over time.

How many AnaptysBio (ANAB) RSUs does the CFO hold after this grant?

After this grant, the Form 4 shows the CFO holding 25,765 restricted stock units directly. Each RSU is tied to one underlying share of AnaptysBio common stock, deliverable upon future vesting and settlement events.